Asthme et obésité : mécanismes et pistes thérapeutiques

Guguen, Camille; Launois, Claire; Dormoy, Valérian; Dewolf, Maxime; Dumazet, Antoine; Dury, Sandra; Lebargy, F.; Deslée, G.; Perotin, Jeanne-Marie

doi:10.1016/j.rmr.2019.03.015

Cited by 5 publications

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Значительный интерес представляет особенность клинического течения бронхиальной астмы у пациентов с ожирением из-за того, что ожирение в современном мире расценивается как важная медико-социальная проблема здравоохранения XXI в. [2].…”

Section: Introductionunclassified

Phenotype of bronchial asthma with obesity in combination with chronic coronary heart disease

Simonova

Balandina

2023

jour

View full text Add to dashboard Cite

Objective: to study the clinical characteristics of patients with the phenotype of obese brochial asthma in combination with chronic coronary heart disease. Material and methods: in an open-label clinical trial, two groups of patients with chronic coronary heart disease (CHD) and bronchial asthma (BA) were formed. Patients of group I (n=43) had obesity as a concomitant disease. Group II (n=50) were non-obese patients. All patients underwent a general clinical examination. The results of Holter’s daily monitoring of the electrocardiogram (HMECG), duplex scanning of the brachiocephalic arteries (BCA DS), transthoracic echocardiography (EchoCG), coronaroangiography (CAG), and spirography were evaluated. The results of biochemical blood testing were also evaluated. Results: for patients of group I, the main complaints were shortness of breath (84% vs 62%, p=0,036) and cough (65% vs 40%, p=0,027) compared with patients of the control group. According to the results of echo-CG in this group, signs of overload of the left heart were revealed. The LV EDV score was more significant than in the control group (p=0,034). The thickness of IVS is also more significant in patients of group I (p=0,022). Ultrasound of the common carotid and internal carotid arteries revealed atherosclerotic plaques in 53% of patients of group I vs 30% (p=0,037) of the control group. According to CAG, the prevalence of RCA stenosis was more significant in patients of group I (56% vs 24%, p=0,003). In patients of group I, spirometry showed a more pronounced decrease in OFV1 (64,1±6,7 vs 66,9±7,1, p=0,042). Conclusion: the adipose BA phenotype combined with CHD is characterized by more frequent cough complaints as the equivalent of choking in bronchobstructive syndrome. Also, patients are more likely to note shortness of breath as the equivalent of angina pain and, possibly, the manifestation of respiratory and heart failure. These clinical features of the phenotype are reflected in the results of instrumental examination methods: pronounced atherosclerotic vascular damage, signs of overload of the left heart, a more significant decrease in the FEV1 rate.

show abstract

Section: Introductionunclassified

Phenotype of bronchial asthma with obesity in combination with chronic coronary heart disease

Simonova

Balandina

2023

jour

View full text Add to dashboard Cite

show abstract

Prévalence de l’asthme chez l’adulte en France, données de la cohorte Constances

Delmas

Bénézet

Ribet

et al. 2021

Revue des Maladies Respiratoires

View full text Add to dashboard Cite

Serum concentration of asprosin in new-onset type 2 diabetes

Naiemian

Naeemipour

Zarei

et al. 2020

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background: Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status. Methods: This observational study was performed based on 194 adults (97 newly diagnosed T2DM and 97 healthy individuals). Anthropometric and biochemical variables were determined in all participants. Serum concentrations of asprosin were measured using enzyme-linked immunosorbent assay (ELISA). Results: In patients with T2DM, the serum concentrations of asprosin were significantly higher than the healthy controls (4.18 [IQR: 4.4] vs. 3.5 [IQR: 1.85], P < 0.001). The concentrations of asprosin were significantly correlated with body mass index (BMI) and fasting blood glucose (FBG) in healthy subjects and with BMI, FBG, hemoglobin A1c (HbA1c), homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative insulin check index (QUICKI), triacylglycerol (TAG) and total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) ratio in the T2DM group. In fully adjusted model, the odds ratio (OR) of T2DM with serum concentrations of asprosin was approximately 1.547 (95% CI 1.293-1.850, P < 0.001) compared to the control group. Multiple stepwise regression analysis indicated that FBG and HOMA-IR were independently associated with asprosin in T2DM. Conclusion: Our findings indicated that serum concentrations of asprosin are increased in patients with T2DM. Also, asprosin is correlated with insulin resistance and TC/HDL-C ratio (atherosclerotic risk factor of cardiovascular diseases) in patients with T2DM.

show abstract

Asthme et obésité : mécanismes et pistes thérapeutiques

Cited by 5 publications

References 105 publications

Phenotype of bronchial asthma with obesity in combination with chronic coronary heart disease

Phenotype of bronchial asthma with obesity in combination with chronic coronary heart disease

Prévalence de l’asthme chez l’adulte en France, données de la cohorte Constances

Serum concentration of asprosin in new-onset type 2 diabetes

Contact Info

Product

Resources

About